What Can I Take Instead of HRT After Breast Cancer?

Several effective non-hormonal options exist for managing menopausal symptoms after breast cancer, ranging from prescription medications to behavioral therapies to newer drugs that target the brain’s thermostat without involving estrogen. Because standard hormone replacement therapy has been linked to increased recurrence risk in breast cancer survivors, oncologists and patients have spent decades building an alternative toolkit. That toolkit is now broader and more evidence-based than many people realize, though the best choice depends on which symptoms bother you most.

Why HRT Is Usually Off the Table

The core concern is straightforward. Many breast cancers are hormone receptor-positive, meaning they grow in response to estrogen. Giving systemic estrogen back through HRT can feed any remaining cancer cells. A systematic review and meta-analysis found that HRT significantly increased the risk of breast cancer recurrence compared to placebo, with the risk roughly 80 percent higher in women with hormone receptor-positive disease specifically.¹ Historically, randomized controlled trials showed increased recurrence and mortality among women who used primarily oral HRT after breast cancer.²

The picture is somewhat less alarming for women whose tumors were hormone receptor-negative, where the meta-analysis did not find a statistically significant increase in recurrence with HRT.¹ Even so, most oncologists advise against systemic HRT as a precaution. That leaves you looking for alternatives, and fortunately there are real ones that work.

Prescription Medications for Hot Flashes

Hot flashes and night sweats are the symptoms that drive the most distress. They are often worse in breast cancer survivors than in women going through natural menopause, partly because treatments like tamoxifen and aromatase inhibitors actively lower estrogen levels. The good news is that several non-hormonal prescription drugs have been tested specifically in breast cancer populations and shown genuine benefit.

Venlafaxine, an antidepressant in the SNRI class, is one of the best-studied options. An early randomized controlled trial in breast cancer survivors found that the higher doses reduced hot flash scores by about 60 percent from baseline after four weeks.³ A more recent trial in women with hormone receptor-positive breast cancer on tamoxifen found a roughly 50 percent reduction in hot flash scores at four weeks.⁴ A double-blind trial comparing it head-to-head with clonidine (a blood pressure drug sometimes used off-label for flashes) and placebo confirmed both drugs were effective.⁵ Venlafaxine tends to be tried first because the evidence base is larger, though clonidine remains an option for women who cannot tolerate antidepressants.

Gabapentin, originally developed for seizures, is the other well-tested choice. A large randomized trial of 420 women with breast cancer found that gabapentin at a dose of 900 mg per day reduced hot flash severity scores by about 46 percent at eight weeks, while the lower dose of 300 mg was no better than placebo.⁶ Another study found that gabapentin also improved sleep quality significantly, which matters because night sweats and sleep disruption often go hand in hand.⁷ The downside is that gabapentin causes dizziness and drowsiness in a meaningful number of people. That same study noted more than a quarter of patients stopped the drug because of side effects.

Oxybutynin, a drug normally prescribed for overactive bladder, is a less widely known option that has shown promising results. A randomized, double-blind trial found that both the 2.5 mg and 5 mg doses significantly outperformed placebo for reducing hot flash frequency and severity in women with or without breast cancer.⁸ The dry mouth that comes with oxybutynin is predictable given how the drug works, but some women find it a worthwhile trade-off.

A Drug Interaction You Need to Know About

If you are taking tamoxifen, the choice of antidepressant for hot flashes matters a great deal. Tamoxifen is not active on its own; your body has to convert it into its active form, endoxifen, through a liver enzyme called CYP2D6. Some antidepressants block that enzyme, which means tamoxifen cannot do its job properly.

The worst offenders are paroxetine and fluoxetine, both of which are potent CYP2D6 inhibitors. Research found that among women with normal CYP2D6 genes, those taking CYP2D6-inhibiting antidepressants had endoxifen levels about 58 percent lower than those who were not.⁹ Venlafaxine, by contrast, is a weak CYP2D6 inhibitor and reduced endoxifen levels only slightly. For this reason, clinical guidelines specifically recommend against using paroxetine or fluoxetine alongside tamoxifen.¹⁰ If your doctor suggests an antidepressant for hot flashes and you are on tamoxifen, make sure they are aware of this interaction. Venlafaxine or gabapentin are the safer choices in that context.

Newer Drugs That Target the Brain’s Thermostat

The most exciting development in this space is a new class of medications that work through a completely different pathway. Your brain regulates body temperature through a system involving neurokinin B receptors (NK3 receptors) in the hypothalamus. Hot flashes happen when falling estrogen destabilizes this system. The new drugs block those receptors directly, reducing hot flashes without touching estrogen levels at all.

Elinzanetant was tested specifically in breast cancer patients taking endocrine therapy in the OASIS-4 trial. By week four, women on elinzanetant experienced about 6.5 fewer moderate-to-severe hot flash episodes per day compared to baseline, versus about 3 fewer in the placebo group. By week twelve, the reduction grew to about 7.8 fewer episodes daily.¹¹ The trial also showed improvements in sleep and menopause-specific quality of life, with a favorable safety profile.¹²

Fezolinetant, which works on the same pathway, has also been studied in breast cancer patients. A recent report found that about 97 percent of patients reported improvement in hot flashes, with roughly three-quarters noting significant improvement and symptom relief occurring within a week for most patients.¹³ These NK3 receptor antagonists represent a genuinely new approach and are particularly appealing because they do not interfere with tamoxifen metabolism or estrogen levels.

Managing Vaginal Dryness and Discomfort

Hot flashes get the most attention, but vaginal dryness, burning, and painful sex are often the symptoms that affect quality of life the most profoundly over time. The medical term for this cluster of symptoms is genitourinary syndrome of menopause, and it tends to get worse rather than better as years pass without estrogen.

Non-hormonal vaginal moisturizers and lubricants are the first-line recommendation for breast cancer survivors. International guidelines support them as initial treatment, especially for mild to moderate symptoms.¹⁴ A randomized trial found that a non-hormonal vaginal moisturizer significantly improved vaginal and vulvar health over 16 weeks compared to lubricant alone, with measurable gains in tissue elasticity, moisture levels, and pH balance.¹⁵ Moisturizers are meant to be used regularly (a few times per week), not just before sex. Lubricants are for sex specifically. Using both is common and reasonable.

Hyaluronic acid vaginal gel is another non-hormonal option that works by drawing water into the vaginal tissue. A study of postmenopausal patients with hormone receptor-positive breast cancer found that 12 weeks of hyaluronic acid gel improved vulvovaginal health and sexual function.¹⁴ It is available without a prescription in many countries and can be a useful starting point.

The Low-Dose Vaginal Estrogen Question

This is where things get genuinely complicated. Unlike systemic HRT (pills or patches that send estrogen throughout your body), low-dose vaginal estrogen is applied locally and delivers only a small amount of hormone directly to vaginal tissue. The question is whether even that small amount is safe after breast cancer.

A large study of breast cancer survivors found no evidence of increased breast cancer-specific mortality in women who used vaginal estrogen therapy, including among those with estrogen receptor-positive disease and those using aromatase inhibitors.¹⁶ That is reassuring, but a meta-analysis of estradiol and estriol preparations found that they did increase serum estradiol levels on average, though the rise was modest. The authors concluded that while low-dose vaginal estrogen had the smallest effect on blood estrogen levels and the most evidence, safety remains unclear, especially for women on aromatase inhibitors, and that the goal should be to keep concentrations as low as possible.¹⁷

In practice, many oncologists will consider low-dose vaginal estrogen for breast cancer survivors with severe vaginal symptoms that do not respond to non-hormonal approaches, particularly for women whose tumors were hormone receptor-negative. The decision is individualized and usually involves a conversation between you, your oncologist, and your gynecologist about the trade-offs.

DHEA and Ospemifene for Sexual Health

Vaginal DHEA (dehydroepiandrosterone, sold as prasterone) is a different approach. DHEA is converted into both estrogen and testosterone locally in the vaginal tissue but is not itself an estrogen. A pilot study in breast cancer survivors on aromatase inhibitors found that vaginal prasterone dramatically improved dyspareunia scores and vaginal health while keeping blood estradiol levels low and stable over six months.¹⁸ A trial comparing two doses of vaginal DHEA to a plain moisturizer found that the higher dose significantly improved overall sexual function and quality of life, with improvements across arousal, lubrication, pain, and satisfaction.¹⁹

Ospemifene is an oral selective estrogen receptor modulator (SERM) that acts like estrogen in vaginal tissue but blocks estrogen in breast tissue. A retrospective analysis comparing vaginal estriol, vaginal DHEA, and ospemifene in cancer survivors found that all three increased the rate of sexual activity and improved sexual function scores, with no significant endometrial thickening or cancer recurrence observed in any group over six months.²⁰ Ospemifene and vaginal DHEA are both options that your oncology team might consider when non-hormonal moisturizers are not enough.

Protecting Your Bones

Estrogen is the primary protector of bone density in women, and losing it after breast cancer treatment — whether through menopause itself or through aromatase inhibitors that suppress estrogen even further — puts you at elevated risk of osteoporosis and fractures. HRT is the classic bone-protective therapy, but you obviously cannot rely on it. Fortunately, other drugs fill this gap well.

A meta-analysis of 14 randomized controlled trials found that antiresorptive drugs were effective at counteracting the bone loss caused by aromatase inhibitors. Zoledronic acid (an intravenous bisphosphonate) improved bone mineral density by about 5 percent at the lumbar spine and 4 percent at the hip over 12 months compared to controls. Oral bisphosphonates showed gains of about 3 percent at the spine and 2 percent at the hip. Denosumab, an injected antibody, showed the strongest results: about 6 percent improvement at the spine and 4 percent at the hip, and it reduced fracture incidence by about half compared to placebo.²¹ A retrospective comparison of denosumab and alendronate (an oral bisphosphonate) in breast cancer patients confirmed that denosumab led to greater improvement in bone density and fewer vertebral compression fractures.²²

Raloxifene, a SERM, occupies an interesting niche. It increases lumbar spine bone density, reduces the risk of vertebral fractures by roughly 30 to 50 percent, and actually reduces the risk of invasive breast cancer.²³ That dual benefit makes it appealing for breast cancer survivors who need bone protection, though it does carry an increased risk of blood clots and, in post-hoc analyses, fatal stroke.²⁴ If you are on an aromatase inhibitor, routine bone density monitoring is standard, and your team will likely recommend one of these treatments if bone loss is detected.

Cognitive Behavioral Therapy and Exercise

Not everything that helps needs to come from a pharmacy. Cognitive behavioral therapy, specifically adapted for menopausal symptoms, has a solid evidence base in breast cancer survivors. A multicenter randomized trial found that CBT significantly decreased the perceived burden of hot flashes and night sweats and increased sexual activity in breast cancer patients.²⁵ CBT does not make hot flashes physically disappear, but it changes how much they bother you and interfere with your life, which turns out to be a meaningful and lasting benefit.

An internet-based version of CBT has also been tested and worked well, with significant improvements in perceived hot flash impact and sleep quality that lasted through 24-week follow-up.²⁶ This matters for accessibility — you do not necessarily need to find a specialist therapist in your city.

Regular exercise also deserves attention, though not specifically for hot flashes. A systematic review and meta-analysis found that combined aerobic and resistance training significantly improved cardiovascular fitness and reduced body weight and BMI in breast cancer survivors.²⁷ A randomized trial in postmenopausal breast cancer survivors found that exercise training improved heart rate recovery and showed trends toward lowering resting heart rate and blood pressure.²⁸ Since you cannot use HRT for cardiovascular protection either, exercise fills some of that gap.

Black Cohosh, Soy, and Other Herbal Remedies

Many women turn to herbal products first because they seem gentler or more natural. The evidence here is decidedly mixed, and it is worth being honest about that.

Black cohosh is probably the most popular herbal supplement marketed for menopausal symptoms. A randomized trial specifically in women with a history of breast cancer found that it was not significantly better than placebo for reducing hot flash number or intensity.²⁹ A systematic review confirmed that the evidence on effectiveness is divided: some benefits show up when compared to baseline, but not when properly compared to placebo.³⁰ The good news is that black cohosh does appear to be safe for women with a history of breast cancer.³¹ It probably will not hurt you, but it probably will not do much either.

Soy isoflavones are more complicated. They are phytoestrogens — plant compounds structurally similar to human estrogen that can bind to estrogen receptors. A meta-analysis found an inverse correlation between soy isoflavone consumption and breast cancer risk in both pre- and postmenopausal women, suggesting soy foods are protective rather than harmful.³² Phytoestrogens can bind weakly to estrogen receptors and in some circumstances can actually inhibit estrogen-driven growth, though only at high doses.³³ That said, the evidence for soy supplements reducing hot flashes after breast cancer is not strong enough for a clear recommendation. Eating soy foods as part of a normal diet is generally considered safe for breast cancer survivors, but megadose soy supplements are a different matter and should be discussed with your oncologist.

Acupuncture and Wearable Cooling Devices

Acupuncture has been studied as a hot flash treatment in breast cancer patients taking antiestrogen therapy. A pilot study found that hot flash severity dropped by 70 to 95 percent in all patients during a course of acupuncture, with benefits maintained four weeks after the final session.³⁴ The study was small and unblinded, so the results need to be taken cautiously — acupuncture studies are notoriously difficult to control for the placebo effect. Still, for women who want a drug-free approach and are comfortable with acupuncture, the risk is minimal and the anecdotal benefit is real for some.

On the more inventive end of the spectrum, a wrist-worn cooling device was recently tested in a trial that included breast cancer patients. The device reduced severe hot flash episodes by about 46 percent overall and by about 41 percent in the breast cancer subgroup specifically, with no adverse events reported.³⁵ This is still early evidence, but the appeal of a drug-free, side-effect-free device is obvious, and the technology is likely to improve. For women who want something they can combine with medication or use on its own for milder symptoms, cooling devices are worth watching.

Putting Together Your Own Plan

The reality is that most breast cancer survivors end up using a combination of approaches rather than finding a single replacement for HRT. You might take venlafaxine or gabapentin for hot flashes, use a vaginal moisturizer and hyaluronic acid gel for dryness, take a bisphosphonate or denosumab for bone protection, and layer in CBT or exercise for sleep and overall well-being. The specific mix depends on your tumor characteristics, which endocrine therapy you are on, how severe your symptoms are, and what side effects you are willing to tolerate. Your oncologist and a menopause-aware gynecologist working together can tailor the approach in a way that keeps you safe and keeps your quality of life from falling through the floor. The options are imperfect substitutes for HRT, but they are real, they are evidence-based, and collectively they cover most of the symptoms that make menopause after breast cancer so difficult.